Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus XELOXIRI as neoadjuvant therapy for locally advanced rectal cancer
ChiCTR2400079964Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, capecitabine, oxaliplatin and irinotecan in rectal cancer, sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: pathological complete response rate. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
camrelizumabcapecitabineoxaliplatinirinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2400079964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079964.